ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1767

Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis

Claire Galand1, Fei Liu2, Katherine Vernon2, Ravi Vats2, Christine Lian3, V. Michael Holers4, H. Terence Cook5, David Cuthbertson6, Nader Khalidi7, Curry Koening8, Carol Langford9, Carol McAlear10, Paul Monach11, Christian Pagnoux12, Jason Campagna2, Shelia Violette2 and Peter Merkel10, 1Q32 Bio Inc,, Waltham, MA, 2Q32 Bio Inc, Waltham, MA, 3Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, 4University of Colorado Anschutz Medical Campus, Aurora, 5Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, 6University of South Florida, Tampa, 7McMaster University, Hamilton, ON, Canada, 8University of Texas Dell Medical School, Austin, TX, 9Cleveland Clinic, Moreland Hills, OH, 10University of Pennsylvania, Philadelphia, PA, 11VA Boston Healthcare System, Boston, MA, 12Mount Sinai Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Biomarkers, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Vasculitis – ANCA-Associated (1764–1769)

Session Type: Abstract Session

Session Time: 10:45AM-11:00AM

Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and through blood vessel walls. NETs carry antimicrobial peptides, myeloperoxidase, proteinase 3, and alternative pathway (AP) complement protein split products. AAV is typically described as pauci-immune, with renal and other tissues often reported as C3 negative.This study aimed to characterize complement activation in affected tissue in AAV using novel techniques to identify active complement as compared to C3d deposition. C3d is a covalently membrane-bound biomarker generated by C3 cleavage that demonstrates extended tissue half-life.

Methods: Immunofluorescence (IF) staining was performed using an anti-C3c polyclonal antibody (Dako) and a novel anti-C3d monoclonal antibody (mAb, 3d8b mouse IgG1). IF was conducted on renal biopsy samples from patients with AAV (n=32), IgA nephropathy (IgAN, n=29), C3 glomerulonephritis (C3G, n=9), and class III lupus nephritis (LN, n=30), and skin biopsy samples from patients with leukocytoclastic vasculitis (LCV, n=37), and skin lesions in AAV (n=4). Immunohistochemistry (IHC) staining of C3d was performed on biopsy samples of kidney (n=8), skin (n=3), lung (n=5), and sinus (n=2) from patients with AAV. Immunostainings (IF and IHC) were semi-quantitatively scored. Renal biopsy IF intensity was further evaluated for digital quantification using image analysis software.

Results: IF staining detected active complement (anti-C3c) and C3d deposition (anti-C3d) in the glomeruli of AAV, IgAN, C3G, and LN) (Figure 1). Both semi-quantitative scoring and digital quantification revealed a moderate glomerular IF intensity in AAV and IgAN, and a higher intensity in C3G and LN. A distinct glomerular staining pattern with C3c/C3d was seen in AAV and IgAN with deposition more in mesangium than capillaries, as compared to C3G and LN in which C3c/C3d deposited equally in mesangium and capillaries. IHC staining of AAV renal tissue confirmed C3d deposition in glomeruli and revealed extra-glomerular small vessels (Figure 2); 3/6 of these same biopsies tested negative for C3 by routine diagnostic immunostaining. IF staining detected active complement and C3d deposition on superficial dermal vasculature in LCV. Semi-quantitative scoring demonstrated higher anti-C3c staining than anti-C3d IF intensity in four AAV-LCV samples, as compared to non AAV-LCV samples (Figure 3). IHC staining of FFPE tissue also detected C3d deposition in skin, lung, and sinus biopsies from AAV patients.

Conclusion: Immunostaining for complement AP fragments, particularly C3d, reveals evidence of complement activation in AAV in kidney, skin, lung, and sinus, including biopsies deemed negative by routine C3 staining. These data demonstrate that glomerulonephritis in AAV is less “pauci-immune” than previously considered. These findings also suggest that the complement AP contributes to the pathogenesis of AAV and that treatment using an anti-C3d tissue targeted AP inhibitor approach could mitigate inflammation-related damage in AAV.

Supporting image 1Figure 1. Immunofluorescent staining developed to capture complement fragments demonstrates glomerular complement activation in frozen kidney biopsies from patients with ANCA-associated vasculitis, in comparison to other glomerulonephritides and normal tissue. Anti-C3c and anti-C3d stainings (A, representative images) were semi-quantitatively scored (B-C) and evaluated for digital quantification (D-E).

Supporting image 2Figure 2. Histochemistry staining reveals the presence of C3d deposition in extra-glomerular kidney small vessels, in formalin-fixed-paraffin-preserved kidney biopsies from patients with ANCA-associated vasculitis.

Supporting image 3Figure 3. Immunofluorescent staining in lesional skin biopsies (A, representative images) reveals a higher level of complement activation in biopsy specimens of leukocytoclastic vasculitis from patients with ANCA-associated vasculitis (AAV-LCV) compared to samples from patients without AAV (Non AAV-LCV) (B).


Disclosures: C. Galand: Q32 Bio, 3; F. Liu: Q32 Bio, 12,, 3; K. Vernon: Q32 Bio, Inc., 11; R. Vats: None; C. Lian: None; V. Holers: Q32 Bio, 12,, 2; H. Cook: Novartis, 2, Q32Bio, 2, Sobi, 1; D. Cuthbertson: None; N. Khalidi: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, GlaxoSmithKlein(GSK), 6, Mallinckrodt, 6, NS Pharma, 5, Otsuka, 6, Roche, 2, Sanofi, 5; C. Koening: Amgen, 1, Boehringer-Ingelheim, 1; C. Langford: AbbVie/Abbott, 12, Non-paid consultant, AstraZeneca, 5, 12, Non-paid consultant, Bristol-Myers Squibb(BMS), 5, 12, Non-paid consultant, GlaxoSmithKlein(GSK), 5, NS Pharma, 5; C. McAlear: None; P. Monach: Boehringer-Ingelheim, 2; C. Pagnoux: AstraZeneca, 1, ChemoCentryx, 1, GlaxoSmithKlein(GSK), 1, 5, InflaRx GmbH, 1, otsuka, 1, 5, Pfizer, 1, 5, Roche, 1, 5; J. Campagna: None; S. Violette: Mediar Therapeutics, 12,, 1, Q32 Bio, 12,, 3, 8, 10, Triveni, 12,, 1; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2.

To cite this abstract in AMA style:

Galand C, Liu F, Vernon K, Vats R, Lian C, Holers V, Cook H, Cuthbertson D, Khalidi N, Koening C, Langford C, McAlear C, Monach P, Pagnoux C, Campagna J, Violette S, Merkel P. Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/identification-of-c3-complement-fragments-in-lesional-tissues-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-c3-complement-fragments-in-lesional-tissues-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology